Jun 2026 (Q3 FY26) — Aug 13, 2026
cbdMD, Inc. Q3 FY26 — Top-line Growth Amidst Regulatory Headwinds and Strategic Investments
Read the full callcbdMD (YCBD) earnings
- Jun 2026
- Jun 2026 (Q3 FY26)
- Sep 2025
cbdMD earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 5.6 | +20.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -20.4 | −0.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -1.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.35 −2.78% · −$0.01
Performance −69.6% 1Y
1Y: $1.15 on 17 Oct 2025 → $0.35. High $2.27 (17 Dec 2025), low $0.35 (14 Oct 2026).
- Previous close
- $0.36
- 52-week range
- $0.35 – $2.27
- One year
- −69.57%
Overview
- Symbol
- YCBD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
cbdMD earnings calls (YCBD)
Financials
What the filings say
Net profit, year on year: −26% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Operating profit | -0 | -0 | -0 | -1 | -1 | -0 | -1 | -1 |
| Operating margin | −7.0% | −1.7% | −10.2% | −19.6% | −14.5% | −5.7% | −14.2% | −20.4% |
| Profit before tax | -0 | 0 | -0 | -1 | -1 | -0 | -1 | -1 |
| Net profit | -0 | 0 | -0 | -1 | -1 | -0 | -1 | -1 |
| EPS ($ per share) | — | 1.73 | -1.90 | -0.21 | — | -0.04 | -0.08 | -0.11 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -7 | -60 | -47 | -73 | -147 | -174 | -182 | -179 |
| Total liabilities | 1 | 57 | 32 | 22 | 9 | 7 | 9 | 3 |
| Fixed assets | 0 | 2 | 3 | 3 | 1 | 1 | 0 | 0 |
| Investments | 1 | 0 | 0 | 0 | 0 | — | — | — |
| Total assets | 15 | 95 | 111 | 125 | 41 | 16 | 11 | 10 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6 | -15 | -11 | -14 | -15 | -4 | -0 | -1 |
| Cash from investing | -1 | -2 | -2 | -3 | -1 | 1 | -0 | -0 |
| Cash from financing | 10 | 18 | 22 | 28 | -4 | -1 | 1 | 1 |
| Capital expenditure | -0 | -1 | -1 | -0 | -1 | -0 | -0 | -0 |
| Free cash flow | -6 | -17 | -12 | -14 | -16 | -5 | -1 | -2 |
Insider filings
10 filings between Nov 28, 2025 and Apr 14, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.28M
3 sales by 1 insider
Compensation
not trading decisions- 7
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Crosnoe Clark R. | — | $1.28M | Dec 17, 2025 |
Latest filings (22)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Apr 14, 2026 | Raines William F III Director | Award | 1,572 | $0 |
| Apr 14, 2026 | Stephen Scott G. Director | Award | 1,572 | $0 |
| Apr 14, 2026 | Sellers Bakari T. Director | Award | 1,572 | $0 |
| Apr 14, 2026 | Swift Sibyl Nichole Director | Award | 1,572 | $0 |
| Apr 14, 2026 | Roe Kevin Charles Director | Award | 1,572 | $0 |
| Apr 14, 2026 | Porter Jeffrey H Director | Award | 1,572 | $0 |
| Dec 17, 2025 | Crosnoe Clark R. 10% owner | Sale | 461,725 | $1.07M |
| Dec 17, 2025 | Crosnoe Clark R. 10% owner | Sale | 69,875 | $163.8K |
| Dec 17, 2025 | Crosnoe Clark R. 10% owner | Sale | 19,101 | $44.8K |
| Nov 28, 2025 | Kennedy Thomas Ronan CEO and CFO | Award | 445,000 | — |
| May 16, 2025 | Swift Sibyl Nichole Director | Award | 1,572 | $0 |
| May 16, 2025 | Stephen Scott G. Director | Award | 1,572 | $0 |
| May 16, 2025 | Sellers Bakari T. Director | Award | 1,572 | $0 |
| May 16, 2025 | Roe Kevin Charles Director | Award | 1,572 | $0 |
| May 16, 2025 | Raines William F III Director | Award | 1,572 | $0 |
| May 16, 2025 | Porter Jeffrey H Director | Award | 1,572 | $0 |
| May 6, 2025 | Roe Kevin Charles Director | Conversion | 23,563 | — |
| May 6, 2025 | Kennedy Thomas Ronan CEO and CFO | Conversion | 67,869 | — |
| May 6, 2025 | Porter Jeffrey H Director | Conversion | 465,955 | — |
| May 6, 2025 | Porter Jeffrey H Director | Conversion | 61,750 | — |
| May 6, 2025 | Porter Jeffrey H Director | Conversion | 41,275 | — |
| May 6, 2025 | Porter Jeffrey H Director | Conversion | 4,550 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for cbdMD, Inc.
Free account. Everything above stays public.
Write why you follow cbdMD, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading